Skip to main content
American Academy of Neurology Annual Meeting
newsroom
Menu
Menu
Main navigation
Home
Featured Diseases & Conditions
COVID-19
Depression Care 360
HIV Management
HIV Prevention
Pediatric Influenza
Psoriatic Arthritis
Resources
Commentary
Disease State Directory
FDA Alerts
Pearls
Podcasts
Polls
Q&As
Quizzes
Research Summaries
Slideshows
Videos
Events & Education
Consultant360's Practical Updates in Primary Care
CME
Publication
About Consultant
Consultant Current Issue
Consultant Early View
Consultant Archive
Author Guidelines
Case Report Templates
FAQ
Advertising With Consultant360
Search
Login
Menu
Menu
Main navigation
Home
Featured Diseases & Conditions
COVID-19
Depression Care 360
HIV Management
HIV Prevention
Pediatric Influenza
Psoriatic Arthritis
Resources
Commentary
Disease State Directory
FDA Alerts
Pearls
Podcasts
Polls
Q&As
Quizzes
Research Summaries
Slideshows
Videos
Events & Education
Consultant360's Practical Updates in Primary Care
CME
Publication
About Consultant
Consultant Current Issue
Consultant Early View
Consultant Archive
Author Guidelines
Case Report Templates
FAQ
Advertising With Consultant360
Multiple Sclerosis
Poll: Newer vs Injectable DMTs for Pediatric MS
Copied to clipboard
<section><h2><h2>For the initial treatment of pediatric multiple sclerosis, do you choose to treat your patients with newer or injectable disease-modifying therapies (DMTs)?</h2></h2></section><section><h2>Newer DMTs</h2></section><section><h3>Injectable DMTs</h3></section>
Article Info
Poll: Newer vs Injectable DMTs for Pediatric MS https://consultant360.com/node/37527
Submit Feedback
Email Address
Name
First
Last
Feedback
Send Mail To
